StockNews.AI
DRMA
StockNews.AI
209 days

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

1. Dermata plans to sell 2,007,880 shares at $1.27 each. 2. This private placement includes warrants exercisable at $1.27.

3m saved
Insight
Article

FAQ

Why Bearish?

Issuing new shares can dilute existing shareholder value, impacting price negatively. Previous share offerings have led to similar declines in share prices.

How important is it?

The financing could impact future growth and shareholder value significantly, hence an important development.

Why Short Term?

The immediate dilution likely affects DRMA's stock performance soon after approval.

Related Companies

NASDAQ:DRMANASDAQ:DRMAW
SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,007,880 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 2,007,880 shares of common stock at a purchase price of $1.27 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrant in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The warrants will have an exercise price of $1.27 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants and will expire five years from the effective date of stockholder approval.

Related News